Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mesalamine in ulcerative colitis.

J M Fitzgerald1, T D Marsh

  • 1Department of Pharmacy Services, Hartford Hospital, CT 06115.

DICP : the Annals of Pharmacotherapy
|February 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iron mother- protocol for a randomised controlled trial of daily versus alternate day ferrous fumarate for the treatment of iron deficiency anaemia in pregnancy.

Contemporary clinical trials communications·2025
Same author

Effect of Tooth Bleach on Dentin Fatigue Resistance in Situ.

Operative dentistry·2023
Same author

Stability of hippocampal subfield volumes after trauma and relationship to development of PTSD symptoms.

NeuroImage·2021
Same author

Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study.

Respiratory research·2020
Same author

Effects of long-term inhaled corticosteroid treatment on fragility fractures in older women: the Manitoba BMD registry study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5.

Pulmonary pharmacology & therapeutics·2019
Same journal

Eradication of methicillin-resistant Staphylococcus aureus vaginitis with mupirocin.

DICP : the annals of pharmacotherapy·1991
Same journal

Ketorolac formulary restriction and usage evaluation.

DICP : the annals of pharmacotherapy·1991
Same journal

Oral vancomycin-induced rash: case report and review of the literature.

DICP : the annals of pharmacotherapy·1991
Same journal

Imipenem/cilastatin drug utilization evaluation in a large community hospital.

DICP : the annals of pharmacotherapy·1991
Same journal

Pharmacist involvement in Society of Critical Care Medicine.

DICP : the annals of pharmacotherapy·1991
Same journal

Early anticoagulation therapy in deep vein thrombosis.

DICP : the annals of pharmacotherapy·1991
See all related articles

Sulfasalazine for ulcerative colitis causes side effects in 20% of patients. Mesalamine enemas are effective for distal ulcerative colitis but are costly, reserved for refractory cases.

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Sulfasalazine is a long-standing treatment for ulcerative colitis.
  • Adverse effects, often linked to the sulfapyridine component, affect up to 20% of patients.
  • 5-aminosalicylic acid (5-ASA) is the other active component of sulfasalazine.

Purpose of the Study:

  • To evaluate the efficacy of mesalamine enemas in treating ulcerative colitis.
  • To compare mesalamine enemas with conventional treatments for ulcerative colitis.

Main Methods:

  • Review of clinical trials on mesalamine enema preparations.
  • Analysis of efficacy in refractory cases of distal ulcerative colitis, proctitis, and proctosigmoiditis.

Main Results:

  • Mesalamine enemas demonstrated efficacy in treating refractory distal ulcerative colitis, proctitis, and proctosigmoiditis.

Related Experiment Videos

  • Mesalamine is the only 5-ASA enema currently available in the U.S.

    • Conclusions:

    • Mesalamine enemas are an effective treatment option for specific forms of ulcerative colitis.
    • Due to higher costs, mesalamine enemas should be reserved for patients intolerant or refractory to conventional therapies.